SOLENO THERAPEUTICS INC — Key Metrics
13 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Cash-Flow Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
EPS (Diluted)↑+106.9% +$6
$0
Book Value Per Share↑+156.8% +$5
$9
Free Cash Flow Per Share↑+117.1% +$6
$1
Cash Per Share↓-66.6% -$3
$1
Revenue Per Share
$4
OCF Per Share↑+117.1% +$6
$1
Return on Equity↑+103.6pts
6.0%
Return on Assets↑+66.2pts
4.7%
Return on Invested Capital↑+81.0pts
2.4%
Debt to Equity
0.11
Current Ratio↑+107.1% +$3
5.80
Quick Ratio↑+98.3% +$3
5.55
Asset Turnover
0.43
Days Sales Outstanding
54.07
Days Payables Outstanding
1681.03
Days Inventory On Hand
2031.02
Cash Conversion Cycle
404.07
R&D / Revenue
21.3%
SBC / Revenue
24.1%
Capex / Revenue
0.0%
Working Capital↑+1942.7% +$280M
$294M
Net Current Asset Value↑+5093.0% +$237M
$242M
Invested Capital↑+2710.0% +$482M
$500M
OCF / Net Income↑+149.4% +$1
2.24
FCF / Net Income↑+148.8% +$1
2.24
Accruals Ratio (Sloan)↑+4.2pts
-4.6%
Net Debt↓-1099.8% -$234M
$-256M
Net Debt / EBITDA↓-3203.2% -$23
-22.36
Interest Coverage
1.72
Cash Coverage
8.55
Capex Coverage↑+150.8% +$2K
641.07
Tangible Common Equity↑+8535.6% +$440M
$445M
TCE / Total Assets↑+64.5pts
79.0%
Goodwill / Total Assets
12.9%
NOPAT↑+137.8% +$34M
$9M
Cash ROIC↑+99.5pts
11.8%
WC / Revenue
154.6%
Capex / D&A↑+222.9% +$0
0.04
Reinvestment Rate↓-26.8pts
-20.7%
Total Payout Ratio
479.4%
Asset Growth vs Revenue Growth
-171.0%
Book Value 5Y CAGR↑+19.2pts
58.1%
Stock Price (FY-end)↑+652.8% +$40
$46
Market Cap↑+7315.9% +$2.39B
$2.43B
P/E Ratio
116.10
P/S Ratio
12.74
P/B Ratio↑+193.1% +$4
5.39
P/TB Ratio↓-14.1% -$1
5.45
P/OCF Ratio
51.83
P/FCF Ratio
51.91
Enterprise Value↑+18930.4% +$2.16B
$2.17B
EV / EBITDA
189.82
EV / Sales
11.40
EV / FCF
46.44
FCF Yield↑+86.9pts
1.9%
Shareholder Yield↑+12.3pts
2.2%
Buyback Yield
4.1%
R&D Yield↓-63.9pts
1.7%
Capex Yield↓-0.1pts
0.0%
Graham Number
$9
Shares Variation (YoY)
30.4%
Beta (5Y)↓-43.6% -$0
0.46
Cost of Equity↓-1.8pts
6.8%
Cost of Debt (after tax)
11.0%
52W High↑+78.8% +$39
$88
52W Low↑+591.7% +$36
$43
Trailing Return 1Y↑+82.1pts
3.3%
Trailing Return 5Y↑+148.7pts
59.1%
F-Score (Piotroski)↑+400.0% +$4
5.00
Z-Score (Altman)
12.75
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.